UPDATE ON REFOCUSING OPERATIONS

XTL Biopharmaceuticals Ltd., a biopharmaceutical company developing drugs against hepatitis, today announced that it is implementing an additional step in the Company's business plan designed to re-focus the Company's resources on the development of its lead hepatitis C programs, XTL-6865, currently in a Phase I clinical trial, and XTL-2125, which is pending the commencement of a Phase I clinical trial.

Biotech Intelligence (http://www.biotech-intelligence.com/html/html/d5de19bf4a98b0fcbb56dc91e92e1839.html)